Heart Failure NHP Model
At Prisys Biotech, we specialize in providing high-value non-human primate (NHP) models that bridge the gap between preclinical research and clinical application. Our cynomolgus monkey heart failure (EFrHF) model is designed to closely replicate the human disease pathway from acute myocardial infarction (AMI) to chronic heart failure. This model offers pharmaceutical and biotech companies a powerful and clinically relevant platform to accelerate cardiovascular drug development.
Why Choose Prisys Biotech's Heart Failure Model?
- Clinically Relevant and Predictive
Cynomolgus monkeys share close anatomical and physiological similarities with humans, especially in cardiovascular function and Heart Failure drug metabolism. Our model reflects the complex clinical progression of human heart failure, enhancing confidence in translational outcomes.
- Comprehensive Evaluation Platform
Our translational research platform combines clinical-grade imaging, biomarker analysis, pathology, and physiological monitoring. This integrated approach provides multi-dimensional data to support both mechanism-of-action studies and therapeutic efficacy evaluations.
- Proven Expertise and Reliability
Backed by a team of experienced veterinarians, scientists, and preclinical physicians, Prisys Biotech ensures precision in Heart Failure model development and reliability in data generation. We bring over a decade of expertise in building innovative NHP disease models that support IND-enabling studies.
Study design and clinical endpoints
Prisys Biotech's Heart Failure NHP Model induced using digital subtraction angiography (DSA)-guided catheterization, enabling precise, minimally invasive vascular intervention.
Study design：
Acute phase: ECG shows ST-segment elevation and Q waves, confirming AMI.
Chronic phase: T-wave flattening and sustained ischemic changes, progressing into chronic heart failure.
Translational Endpoints for Drug Development:
Cardiac Imaging: MRI, DSA, echocardiography, and PET-CT.
Biomarkers: Cardiac enzymes (CK, CK-MB, LDH), inflammatory markers (CRP, cytokines).
Pathology: Routine CBC, serum chemistry, and histopathology at study endpoints.
Physiological Monitoring: Continuous ECG and blood pressure tracking.
key result and figure legend in Heart Failure NHP model
Partner with Prisys Biotech
By combining advanced modeling techniques with clinical-grade assessment tools, Prisys Biotech delivers a highly translational platform for evaluating cardiovascular (Heart Failure) therapies. Our cynomolgus monkey heart failure model not only helps elucidate mechanisms of action but also informs dose selection and trial design-providing critical insights to move your program forward with confidence.
Let Prisys Biotech be your partner in accelerating the discovery and development of innovative heart failure treatments.
Hot Tags: heart failure nhp model, research, study, monkey, gene therapy, AMD Nonhuman Primates Disease Model, Myopia Hyperopia Nonhuman Primates Disease Model, NHP diseasepharmacology, NHP monkey Disease Models, NHP Safety evaluation pharmacology, peptide PK pharmacology
You Might Also Like
Send Inquiry